Urinary phthalates and body mass index in preschool children: The MIREC Child Development Plus study

Jillian Ashley-Martin1, Linda Dodds2, Tye E Arbuckle1

  • 1Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.

Insights

Childhood exposure to di-n-butyl phthalate (DnBP) may increase obesity risk in preschoolers. Higher DnBP levels were linked to elevated BMI z-scores in Canadian children aged two to five years.

Area of Science:

  • Environmental Health
  • Pediatric Endocrinology
  • Toxicology

Background:

  • Phthalates are chemicals linked to reproductive and developmental issues.
  • Previous research suggests a link between phthalate exposure and obesity.
  • The association in preschool-aged children remains unclear.

Purpose of the Study:

  • To investigate the relationship between urinary phthalate metabolite concentrations and anthropometric measures in preschool children.
  • To identify specific phthalate metabolites associated with increased risk of childhood obesity.

Main Methods:

  • Cross-sectional study of approximately 200 Canadian children aged 2-5 years.
  • Measurement of 19 urinary phthalate metabolites.
  • Analysis using multivariable linear regression and weighted quantile sum regression.

Main Results:

  • Higher concentrations of di-n-butyl phthalate (∑DnBP) were associated with increased BMI z-scores.
  • ∑DnBP was identified as a priority chemical exposure linked to BMI in preschool children.
  • No significant associations were found for other phthalate metabolites.

Conclusions:

  • Di-n-butyl phthalate (DnBP) is a potential chemical of concern for childhood obesity in Canadian preschoolers.
  • Further research with longitudinal data is needed to confirm these findings.
  • This study highlights the importance of monitoring environmental exposures in early childhood.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
131
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
930
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
106
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
85